Cinciripini, Paul M.
Green, Charles E.
Robinson, Jason D.
Karam-Hage, Maher
Engelmann, Jeffrey M.
Minnix, Jennifer A.
Wetter, David W.
Versace, Francesco
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA017073)
Article History
Received: 9 October 2016
Accepted: 22 February 2017
First Online: 8 March 2017
Compliance with ethical standards
: The University of Texas MD Anderson Cancer Center Institutional Review Board approved the protocol and informed consent.
: Support for this research was provided by grants from the National Institute on Drug Abuse (grant number R01DA017073) to Paul M. Cinciripini and the Cancer Center Support Grant from the National Cancer Institute (grant number P50CA70907) to MD Anderson Cancer Center. Pfizer provided the varenicline and matching placebo.
: Dr. Cinciripini served on the scientific advisory board of Pfizer Pharmaceuticals and conducted educational talks sponsored by Pfizer on smoking cessation (2006–2008) and has received grant support from Pfizer. The other authors declare that they have no conflict of interest.